We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Giulia Petroni
Sanofi SA said late Monday that it has finalized the restructuring of the antibody collaboration for cholesterol treatment Praluent with Regeneron Pharmaceuticals Inc.
The French drug maker said that, starting from April 1, it will supply the alirocumab drug outside the U.S. and Regeneron will supply it in the U.S.
The companies, however, have entered into agreements to support manufacturing needs in the near term.
Sanofi and Regeneron announced their intent to restructure the antibody collaboration for Praluent in December 2019.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
April 07, 2020 01:54 ET (05:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
